GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
GeneDx Holdings Corp. - Class A (WGS)
Company Research
Source: GlobeNewswire
STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry. The new partnership will increase access to GeneDx's extensive de-identified rare disease data set, now available through Komodo Health’s MapEnhance offering, including data from more than 500,000 exomes, enabling biopharma companies to access genetic insights that can help inform drug pipelines and accelerate clinical trial enrollment. “The partnership between GeneDx and Komodo Health represents a milestone in advancing the understanding of rare disease and its associated drug development”, said Melanie Duquette, Chief Growth Officer, GeneDx. "We continue to see increased investment in rare disease drug discovery and want to help accelerate access to these life changing treatments by making our data more
Show less
Read more
Impact Snapshot
Event Time:
WGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WGS alerts
High impacting GeneDx Holdings Corp. - Class A news events
Weekly update
A roundup of the hottest topics
WGS
News
- GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at TD Cowen from $14.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
- GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at BTIG Research from $15.00 to $19.00. They now have a "buy" rating on the stock.MarketBeat
- GeneDx Reports First Quarter 2024 Financial Results and Business HighlightsGlobeNewswire
- GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at BTIG Research from $11.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $6.00 to $11.00. They now have a "neutral" rating on the stock.MarketBeat
WGS
Earnings
- 4/29/24 - Miss
WGS
Sec Filings
- 5/15/24 - Form 4
- 5/3/24 - Form 4
- 4/30/24 - Form 4
- WGS's page on the SEC website